Good day, and thank you for standing by. Welcome to the Richardson Electronics Earnings Call for the Fourth Quarter of Fiscal Year 2022. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one on your telephone. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Ed Richardson, Chief Executive Officer. Please go ahead.
Good morning, and welcome to Richardson Electronics conference call for the fourth quarter of fiscal year 2022. Joining me today are Robert Ben, Chief Financial Officer, Wendy Diddell, Chief Operating Officer and General Manager for Richardson Healthcare, Greg Peloquin, General Manager of our Power & Microwave Technologies Group, and Jens Ruppert, General Manager of Canvys. As a reminder, this call is being recorded and will be available for playback. I'd also like to remind you that we'll be making forward-looking statements. They're based on current expectations and involve risks and uncertainties. Therefore, our actual results could be materially different. Please refer to our press release and SEC filings for an explanation of our risk factors. Fourth quarter sales were $61.6 million, the highest quarterly sales we've achieved since the sale of RFPD in 2011.
Fourth quarter gross margin improved to 32.7% versus 31.8% in the third quarter. Total sales for FY 2022 were $224.6 million, an increase of 26.9% over the prior year. In addition, backlog rose again to $206.2 million, nearly double to where we ended FY 2021. This supports the continued growth we expect to achieve in FY 2023. While power grid tubes are still a significant and growing part of our business, our expanded focus on designing and manufacturing products has driven sales to new levels and positioned us for continued growth in the face of tougher economic conditions. Today, more than 60% of our business comes from products we either manufacture or have manufactured exclusively for us.
In addition, we continue to experience year-over-year growth across all three of our business units during the fourth quarter and full year. Power management solutions that support a green environment is an important growth opportunity and strategic focus. Demand for alternative energy in the face of unprecedented fuel prices is growing. We're benefiting from this trend. From the ultracapacitor modules used in GE wind turbines to future applications, such as production of green hydrogen using microwave generators, our existing and new products are capturing attention and solving customer problems. Demand for our 6 kW magnetron, a product I was told back in the eighties would not be around in five years, continues to grow exponentially, and more consumers choose man-made synthetic diamonds over traditional diamond mining. Diversification is an important component to our long-term success. It's no longer just the semiconductor wafer fabrication market driving the upside in our revenues.
Although this business was particularly strong for us in the Q4, 6.7% of our business in the quarter came from new products. We also saw growth in our EDG product lines to both existing and new customers. Canvys continues to add blue-chip customers to its list of new custom display product wins. Simply put, our business is firing on all cylinders, and I believe we're just getting started. Through a lot of hard work and dedication of our sales, engineering, and manufacturing teams, and the support of our experienced supply chain, finance, and maintenance teams, we're taking the company to new heights. In fact, Q4 was the most profitable quarter the company's had since 2007, which was prior to the sale of two of our divisions.
Our challenge is growing our engineering and manufacturing capabilities quickly to take advantage of significant opportunities underway across many of our global markets. We're investing in people, in our facilities to support the growth and backlog, and to capitalize on new product opportunities that solidify our competitive position in the future. I'll now turn the call over to Robert Ben, Chief Financial Officer, to review our fourth quarter and full year financial performance in more detail. Greg, Wendy, and Jens will provide more details on our fourth quarter performance as well as our new programs.
Thank you, Ed, and good morning. I will review our financial results for our fourth quarter and fiscal year 2022, followed by a review of our cash position. Net sales for the fourth quarter of fiscal 2022 increased 22.1% to $61.6 million, compared to net sales of $50.5 million in the prior year's fourth quarter, due to higher net sales across all three business units. PMT sales increased by $10.4 million or 26.8% from last year's fourth quarter, driven by strong growth from our new power and microwave technology partners for various applications, including power management, Green Energy Solutions, and 5G infrastructure.
Sales for several electron tube product lines, as well as manufactured products for our semiconductor wafer fabrication equipment customers, also increased from the fourth quarter of fiscal 2021. Canvys sales increased by $0.6 million or 7.1% due to strong customer demand in North America. Richardson Healthcare sales increased $0.1 million or 4.1%, primarily due to increases in parts sales and equipment sales, partially offset by lower sales of ALTA750 tubes. In addition to higher revenues, total company backlog increased to $206.2 million in the fourth quarter of fiscal 2022 from $175.6 million at the end of the third quarter of fiscal 2022 and $110.0 million at the end of the fourth quarter of fiscal 2021.
This is the highest level our backlog has been since the sale of RFPD in 2011. Gross margin for the fourth quarter was 32.7% of net sales compared to 32.4% of net sales in last year's fourth quarter. PMT's margin increased to 34.4% from 32.0% due to product mix, including higher sales of the ULTRA3000 and improved manufacturing efficiencies. Canvys gross margin decreased to 30.7% from 35.3% because of higher global freight costs and foreign exchange effects. Healthcare's gross margin was 10.8% in the fourth quarter of fiscal 2022 compared to 29.4% in the prior year's fourth quarter, due to a lower level of absorption and higher level of scrap expense.
Operating expenses were $15.2 million for the fourth quarter of fiscal 2022 compared to $14.0 million in the fourth quarter of fiscal 2021. The increase in operating expenses resulted from higher employee compensation expenses, primarily due to increased incentive expense resulting from the highest level of profitability since the fourth quarter of fiscal 2007. Operating expenses as a percentage of net sales improved to 24.6% during the fourth quarter of fiscal 2022 compared to 27.7% during the fourth quarter of fiscal 2021. The company reported operating income of $5.0 million or 8.1% of net sales for the fourth quarter of fiscal 2022 versus operating income of $2.3 million or 4.6% of net sales in the fourth quarter of last year.
Other expenses for the fourth quarter of fiscal 2022, including interest income and foreign exchange, were $0.2 million compared to other expenses of less than $0.1 million in the fourth quarter of fiscal 2021. The non-cash income tax benefit of $3.5 million for the fourth quarter of fiscal 2022 resulted from the $4.0 million partial reversal of the tax valuation allowance due to evidence of profitability for realizing a portion of the deferred tax assets in the future. Net income was $8.3 million or 13.4% of net sales for the fourth quarter of fiscal 2022 as compared to a net income of $1.9 million or 3.7% of net sales in the fourth quarter of fiscal 2021.
Without the $4.0 million tax valuation allowance adjustment, net income for the fourth quarter of fiscal 2022 was $4.3 million or 6.9% of net sales. Earnings per common share on a diluted basis in the fourth quarter of fiscal 2022 were $0.59 compared to $0.14 per common share on a diluted basis in the prior year's fourth quarter. Excluding the tax valuation allowance adjustment, earnings per common share on a diluted basis were $0.31 for the fourth quarter of fiscal 2022. Turning to a review of the results for fiscal year 2022. Net sales for fiscal year 2022 were $224.6 million, an increase of 26.9% from $176.9 million in fiscal year 2021.
Net sales increased by $40.8 million or 29.7% for PMT, $5.9 million or 20.0% for Canvys, and $1.0 million or 10.1% for Richardson Healthcare. Gross margin decreased to 31.9% from 33.2%, primarily reflecting product mix in PMT, higher global freight costs and foreign exchange effects in Canvys, and increased component scrap expenses for Healthcare. Operating expenses were $55.7 million for the fiscal year, which represented a decrease of $0.2 million from the last fiscal year. The decrease was due to the non-recurrence of a $1.6 million legal settlement in fiscal 2021 and lower legal fees. These decreases were mostly offset by higher employee compensation expenses, including additional incentive expense due to the strong profitability.
Operating expenses as a percentage of net sales improved to 24.8% during fiscal 2022 as compared to 31.6% during fiscal 2021. Operating income for fiscal year 2022 was $16.0 million or 7.1% of net sales as compared to an operating income of $2.9 million or 1.6% of net sales for fiscal year 2021. Other expenses for fiscal 2022, including interest income and foreign exchange, were $0.2 million as compared to other expenses of $0.6 million for fiscal 2021. The income tax benefit of $2.2 million resulted from the $4.0 million partial reversal of the tax valuation allowance.
The company reported net income of $17.9 million or 8.0% of net sales for fiscal year 2022. Versus net income of $1.7 million or 0.9% of net sales for fiscal year 2021. Without the $4.0 million tax valuation adjustment, net income for fiscal 2022 was $13.9 million or 6.2% of net sales. Earnings per common share on a diluted basis in fiscal 2022 were $1.31 compared to $0.13 per common share on a diluted basis in the prior year. Excluding the tax valuation allowance adjustment, earnings per common share on a diluted basis were $1.02 for fiscal 2022. Moving to a review of our cash position.
Cash and investments at the end of the fourth quarter of fiscal 2022 were $40.5 million, compared to $39.1 million at the end of the third quarter of fiscal 2022, and $43.3 million at the end of the fourth quarter of fiscal 2021. The company continues to invest in working capital to support its growth initiatives. Inventory grew to $80.4 million from $73.7 million at the end of the third quarter of fiscal 2022 and $63.5 million at the end of fiscal 2021. The largest portion of the increase for both the fourth quarter and fiscal year 2022 was due to increases in components and work in process for our manufacturing business.
Also, accounts receivable increased to $29.9 million from $25.1 million at the end of fiscal 2021, primarily due to the high sales growth. Capital expenditures were $1.0 million in the fourth quarter of fiscal 2022 versus $0.8 million in the fourth quarter of fiscal year 2021. Approximately $0.7 million related to the investments in our manufacturing business. $0.2 million was for our healthcare business, and $0.1 million was for our IT system. Total capital expenditures were $3.1 million in fiscal 2022 as compared to $2.6 million in fiscal 2021. We expect a higher level of capital expenditures in fiscal year 2023 as we make additional investments in our manufacturing capabilities and facility.
We paid $0.8 million in cash dividends in the fourth quarter and a total of $3.2 million in fiscal year 2022. In addition, based on our current financial position, our board of directors declared a regular quarterly cash dividend of $0.06 per common share, which will be paid in the first quarter of fiscal 2023. Finally, during fiscal 2022, we repatriated $1.5 million to the U.S. from several foreign locations. Our U.S. domiciled cash and cash equivalents balance totaled $25.5 million as of May 28, 2022, the same balance at the end of fiscal 2021. Now I will turn the call over to Greg, who will discuss the results for our Power & Microwave Technologies group.
Thank you, Bob, and good morning, everyone. Sales of the Power & Microwave Technologies group, or PMT, in the fourth quarter of fiscal year 2022 grew 26.8% to $49.3 million, versus $38.9 million in Q4 last year. In addition to a strong sales quarter, PMT achieved excellent book-to-bill ratio of 1.69. Our sales growth and strong bookings confirm another solid quarter for what shaped up to be an excellent FY 2022, with 29.7% growth over prior year. Our gross margin also increased in the quarter to 34.4% versus 32% in the prior year, which was mainly due to continued success in our engineered solutions products for Green Energy applications and an extremely strong quarter for our semiconductor wafer fab equipment business.
Both business units in PMT supported the strong growth we achieved in bookings and billings in the fourth quarter. Our Electron Device Group, or EDG, had an extremely robust quarter in bookings as we continue growing market share from our competition and finding new applications for Legacy Two products, specifically magnetrons used in the development of synthetic diamonds and other green solutions. We also continue to experience excellent growth in our Power and Microwave Group, or PMG, business unit. Over the years, we have added new technology partners and new products targeting RF and power management applications. This includes 5G infrastructure programs as well as programs dedicated to the consistently growing power management and energy storage applications that support green initiatives across our global markets. With respect to 5G and power management, revenues increased by high double digits again in the fourth quarter with a very strong book-to-bill ratio.
PMG experienced exceptional growth in demand for Green Energy applications such as wind energy, electric locomotives, and energy storage. Our recently introduced products, such as the patented Ultra three thousand Pitch Energy Module used in wind turbines, continued to gain traction and increase sales and bookings in the quarter. We are producing the Ultra three thousand with remarkable results in the field and millions of accumulated hours of operation, shipping over 22,000 units in FY 2022. We also saw a major increase in bookings with Enel, Invenergy, Avangrid, and numerous other owner-operators of GE wind turbines. We are in discussions with a major wind turbine OEM for private label development of numerous products, which we hope to announce in the second half of FY 2023. During the fourth quarter, we also received an $18 million order for our power management module used in electric locomotives.
This module, along with products like our ULTRA3000 and ULTRAGEN3000, extends our leadership position by further supporting innovative power management solutions using various technologies. To replace lead acid batteries across numerous markets and applications. Our patent pending ULTRAGEN3000 designed for generators and cellular base stations in critical facilities had great success in the AFHA product trials. We anticipate beta testing should be completed by the end of the calendar year. As I mentioned, we continue to add new products to our portfolio, and we are on schedule to introduce new products and technology partners throughout FY 2023. Our RF microwave components business, also part of PMG, continues to benefit from the high demand associated with 5G microwave communications and Satcom applications.
The use of these applications is driven by people working from remote locations requiring the capability to send large amounts of data. Our entire team has done a great job identifying niche technology partners who collaborate with us globally, and we added more small, innovative suppliers in the fourth quarter. We also continued to invest in and focus on resources to support our growth. We are adding design engineers, field engineers, and manufacturing capabilities across our organization. Our growth strategy has been highly successful over the years, and we will continue to develop new products as well as increase our customer base, revenue and profits by capitalizing on our existing demand creation infrastructure. We are excited to see that over the past fiscal year, our legacy tube business had a strong return in both bookings and billings.
The fourth quarter of FY 22 continued to prove that the demand for our products and services did not go away with the pandemic. We are even more excited about the trends in bookings that will support strong revenue growth in the coming fiscal year. We continue to receive support from our key partners, such as Qorvo, MACOM, Anokiwave, Ellis Materials, Amogreentech, and Fuji Electric. Key tube manufacturers in the industry, such as CPI, Thales, NJRC, and Photonis work with us to manage our customer requirements. Our growing in-house engineering and manufacturing teams did a great job supporting increased demand for current products and new product designs. The team also supported product designs for key growth markets, focusing on Green Energy Solutions as the patented ULTRA3000 and patent pending ULTRAGEN3000 and power management modules for electric locomotives.
I am pleased with the progress we are making. We will continue to identify, develop, and introduce new products and technologies for Green Energy and other power management applications. We remain challenged by longer semiconductor lead times and the overall supply chain. This affects both our component business and engineered solutions products. We are aggressively investing in inventory that should position us to fill the pipeline and ensure we can meet our customers' needs while we collaborate closely with our customers and suppliers. Starting in Q1 FY 2023, earnings release in October, we'll be announcing the new Green Energy Solutions Group. This group is formed out of PMT and will be managed by PMT as we continue to focus on power management applications that support the Green Energy markets globally. I cannot stress enough the value of Richardson Electronics model to our customers and suppliers.
Our unparalleled capability and global go-to-market strategy are unique to the power and RF array market industries. We have developed a strong business model, including legacy products and new technology partners that fit well with our engineered solutions capabilities. Through our steadfast and creative focus on customers, we will continue to excel by taking advantage of opportunities as they arise. Our backlog has never been stronger, and the execution of our strategy has never been better. There's no question our customers and technology partners need Richardson products and support more than ever. With that, I'll turn it over to Wendy Diddell to discuss Richardson Healthcare.
Thanks, Greg. Good morning, everyone. Fourth quarter sales for the healthcare group were $2.9 million, an increase of 4.1% over Q4 of FY 2021. Tube sales were lower than our prior quarter and prior year, due mainly to lower sales in China and Ukraine, while sales from replacement parts and systems were strong. Unfortunately, we had a significant supplier issue in the quarter, forcing us to scrap a number of targets as well as 5 tubes before we temporarily suspended production. As a result, gross margin in the fourth quarter was 10.8% versus 29.4% in Q4 last year. While we are disappointed by this issue, we were able to determine root cause and are now back in full production.
Healthcare full year sales were $11.4 million in FY 2022, 10% above FY 2021 sales of $10.3 million. Both tubes and parts sales increased. System sales were flat due to limited supply. In May, we completed our second ALTA750 G beta, and we're able to do a soft launch of the tube. We are still waiting to receive CE approval, which is required to sell the G tube in Europe and Canada. This is the second tube in the Canon series, and it works on newer Canon CT scanner models. Sales growth will be gradual as we get the ALTA750 G into the market and Canon CT scanners come off of OEM service contracts.
We anticipate sales of our ALTA750 D will also improve as more scanners become available, and because we recently received our MDSAP certification and Canadian device license, allowing our ALTA750 D CT tube to be sold in Canada. We continue to make good progress on the Siemens repaired tube program. This is a series of four tube types, including the Straton Z, MX, MXP, and MXP 46. The Siemens install base is considerably larger than Canon's, and there are no third-party replacement options for these tube types. We are on track to release the repaired Straton Z later in calendar year 2022. The MX and MXP series will follow in 2023. The Siemens program is a critical element to achieving our goal of providing a positive operating contribution to the company by Q4 of FY 2024.
I will now turn the call over to Jens Ruppert to discuss the results for Canvys.
Thanks, Wendy, and good morning, everyone. Canvys engineers, manufactures, and sells custom displays to original equipment manufacturers in industrial and medical markets throughout the world. Canvys delivered an outstanding performance and set a new quarterly record with sales of $9.5 million for the fourth quarter of fiscal 2022. Strong customer demand on a global base drove a 7.1% increase in sales over the same period last year. Global sales grew by 20.0% to $35.2 million in fiscal 2022, the highest revenue since fiscal year 2013, due to an increased demand globally and the addition of new customers and programs. This was a remarkable accomplishment considering the long-term business impact of COVID-19 pandemic.
Gross margin as a percentage of net sales was 30.7% during the fourth quarter of fiscal 2022, down from 35.3% during the fourth quarter of fiscal 2021. Our fiscal year 2022 gross margin as a percentage of sales decreased to 32.0% from 35.0% versus fiscal year 2021. The decrease in gross margin was related to higher component costs, increased freight costs, and foreign currency effects, which impacted many companies around the globe, like Canvys. Extended lead times on several key components remains an issue. However, our close relationship with customers and partners overseas enables us to procure long lead time components, which has helped us maintain our backlog at prior quarter's record level of $52.4 million. Canvys's backlog increased by 52.3% on a year-over-year basis.
Our customers are ensuring product availability in advance, and we have orders on the books that are scheduled to ship up to three years from now. It's important to understand that we serve a highly specialized customer base for whom it is difficult and costly to change out components. We are extremely proud to count many of the top 10 medical device companies worldwide as our long-term customers. In fact, 76% of our fiscal year 2022 revenue came from medical OEM, and all our products are custom-designed to their needs. It takes years getting the product to market, but when we are the supplier of choice, we are designed in for many years to come. All customer orders are binding, and we won't find ourselves in an overstock position.
While we expect the growth in the backlog to level out in the near term, we are optimistic that the high demand for our custom monitors, touchscreens, and all-in-one systems will continue. We recently released our 32-inch 4K monitor platform and the level of interest is encouraging. The product offers high brightness, a wide color gamut, and a plastic housing to optimize the overall weight of the monitor. This platform is customizable with a 12G-SDI interface, PCAP touch, and 3D polarizer options. This high-end product meets medical requirements and is DICOM compliant. We are targeting the robotic navigation and minimally invasive surgery space with this new platform, and we are confident that our product strategy will result in new leads and business growth. During the quarter, we received several new orders from existing and first-time OEM customers.
Some of these include cardiac pulse field ablation, femtosecond laser, intense pulsed light and laser therapy, colposcopy, surgical navigation, C-arm, laser lithotripsy, medical device control in fully integrated operating rooms, robotic-assisted surgery, surgical video documentation, atherectomy laser, and endoscopy. In the non-medical space, our products are used in a variety of commercial industrial applications. This includes CT scanners for inspecting luggage at airports, passenger information systems on buses and trains, human machine interface for process automation, metal 3D printing, and product dispenser for retail applications. We are very pleased with our team's performance. Our strong customer relationship, together with the record backlog position as well for future growth. From the variety of customers and applications, as well as the value of orders from existing and new customers, it is clear we offer our global customers outstanding products and local service.
While our sales organization stays focused on new opportunities, I stay focused on improving the operating performance of the division. Maximizing cash flow and improving Canvys's profitability is an ongoing priority. We continue to work closely with our partners to meet the demand of our customers, particularly with the challenges brought on by industry-wide supply chain delays. I will now turn the call back over to Ed.
Thank you, Jens. Another amazing quarter and year for Canvys. As you can see, there's a lot happening within Richardson Electronics, and I'm encouraged by the positive momentum underway across our business. From Green Energy to new uses for tubes such as magnetrons, from custom displays used by companies like Medtronic and Varian, to very sophisticated CT tubes, our business is growing. We're carefully preserving our cash so we can invest in our employees and our facilities to accommodate the positive demand we're experiencing for engineered solutions. As of now, we're not seeing the impact of a recession on demand for our products, but we're closely monitoring activity and backlog growth across our global markets, and we'll react quickly if needed. At the end of Q1, we'll begin recording a fourth business unit for Green Energy Solutions.
This will highlight the growth in revenue generated from our new solutions, as well as existing products using green applications. Our product roadmap is solid, and we expect to grow sales from new customers, new products, and new applications. We look forward to sharing more details with you in the coming quarters. At this time, we'll be happy to answer some questions. Thank you.
Thank you. As a reminder to ask a question, you will need to press star one on your telephone. Please stand by while we compile the Q&A roster. Our first question comes from Anja Soderstrom with Sidoti. Your line is now open.
Hi. Thank you for taking my questions, and congratulations on an exceptional quarter. A lot of exciting things going on. My first question is gonna be around the Healthcare and sort of the, if you could just clarify what sort of put the weight on the margins there and what we can expect in the coming quarters in terms of that.
Hi, Anja, it's Wendy Diddell. Yeah. We were disappointed obviously in the quarter with the margin, and that, as I mentioned in the presentation, was associated with a supply issue where a key part of the tube that we use, there was a change in the process, and it caused us to lose both targets and 5 tubes. The margin as a result in the fourth quarter was down around 10%. That was also impacted because we had to stop production, so we were considerably under-absorbed. I will mention that when we closed production in the healthcare area, we were able to relocate a lot of the people to other areas of the company, so we didn't lose them completely.
We were able to take advantage of the skills that they have and have them work over in the La Fox manufacturing area working on the wind turbine program and our LAN program. That was a positive. What we can expect going forward, we are back in production. The first quarter, we have not had any supplier issues nor any significant equipment issues, so I would anticipate that the gross margin will go back into the mid you know mid-to-upper 20s%, barring any unforeseen circumstances that could still happen in the next six weeks or so.
Thank you. I think also you mentioned something about Ukraine and China, in terms of the healthcare business. What did you experience there in the fourth quarter, and do you expect that to be sustained or?
Okay.
What do you see there now?
Good question. With respect to Ukraine, one of our significant customers is located there, and they have started buying again. I would expect to see gradual sales coming back from them. They're temporarily located in Poland, and so they're still able to service CT equipment. In China, that's a timing issue. We've already received and shipped a large order in the first quarter. There's no question about the demand or any issue there. It's just a timing issue. I think we'll see that come back in the first quarter.
That was just isolated to the fourth quarter, the issues with Ukraine and China?
Well, Ukraine is variable. Obviously, we have to wait and see how things go there.
Okay. With the PMT business, you've been talking about that, the wind turbine business there, and you have the large order with the NextEra. When can you sort of anticipate a follow-up order from them and what to expect in terms of that?
Thanks, Anja. Yeah, Greg, you wanna answer that?
Sure. We have weekly calls with NextEra. We're working on a number of other products for their wind turbines that we'll be announcing here in the second half. We'll be finishing up phase one sometime at the end of the summer. We'll probably receive the phase two order, which will be similar in size, if not bigger, in our Q2. That was the status as of yesterday morning. It's a great partner. The good news is that we, over the past 18 months, have now 9 different customers, owner operators of wind turbines that are purchasing this product. We have definitely become the incumbent for this product in the industry, especially North America.
We did receive in the quarter, which was amplified the strong bookings quarter, exclusive order and shipments to Invenergy and Enel, which are three now with NextEra, three of the top owner operators of GE wind turbines in North America. It's really growing fast.
Okay. In terms of the beta test for the power stations, when are those concluded? I want to anticipate some orders from there.
Yeah. We received an order for 12 cell towers from T-Mobile. The current beta site testing is happening right now in their facilities there in Phoenix, Arizona. Similar to the ULTRA3000, it's about a 6-month process for them to do all the analysis and get the beta site testing. In terms of production orders, I would expect those in Q3 of our fiscal year, starting with T-Mobile.
Okay. On the Progress Rail, it seems like you're also just scratching the surface there. What can we expect there? Are there other sort of use cases that you could also support them with?
Well, Progress Rail is owned by Caterpillar, and what the benefit of that entire program is, we continue to see other opportunities for other products for Progress Rail and for Caterpillar. The program to date is, we booked in the quarter, as I mentioned, an $18 million order. This product is the lithium module that we ship to Brazil, and they assemble it into the electric locomotive structure and then ship that to customers outside of North America. In the meantime, over the past six months, we've developed the relationship where we're gonna be the manufacturing arm and design arm for products being sold to North American customers, such as Union Pacific, Long Island Rail Road.
We booked a $3.5 million order to build not only the lithium module but what's called the superstructure, which literally is the guts of the electric locomotive. We'll then ship that to Progress Rail, who will then ship it to their customers. We fully expect an add-on order to that in Q1 about a similar amount, about $3.5 million. In terms of content, the $3.5 million, our content's about $1.2 million for that per locomotive. Any customer in North America is asking for, in some cases demanding, that as much content, whether it's the build, assembly, test, support, is in North America. With Richardson's capabilities here, Progress Rail picked us in the fourth quarter to do this program with them. We're very excited about that.
As you saw some press releases, Union Pacific is placing 20 orders for 20 locomotives this fiscal year.
Yeah. Then there are potentially other use cases with Caterpillar as well, or?
Yeah, for different products. You know, it's just.
Yeah.
To be a confirmed agreement as a design and manufacturing arm for a company like Caterpillar, that just gets you in a position where, for example, with Progress Rail, we have a call every week, and there's about 20 engineers on those calls. It's just amazing, the opportunities as everybody tries to go green, and we have this niche power management capabilities here at Richardson, to take advantage of some of these, I call them niche applications. They're quite large for us, but to others that they're kinda niche.
I recommend, if I could, have anyone on that call, because when you hear the 20 engineers talking, anybody who thinks we're a tube distributor will realize real quick that we are that and so much more.
Okay. Well, thank you for that color. Then, in terms of Canvys, it's been very strong growth for you. Is that more catch up from the pandemic, or do you think that's gonna be sustainable?
Hey, this is Jens. I absolutely think that's sustainable. Yeah, we will continue to grow. You know, we have a lot of new opportunities in the pipeline. As I mentioned in my script too, you know, there is the go-to market takes a long time. Sometimes we talk 3, 4, 5 years to the engineers, you know, to get everything going. It's really more not another short-term thing, you know, it's a mid- and long-term thing. We have definitely new opportunities working on, so I anticipate this business further to grow. Yeah.
Okay, thank you. Then, what kind of currency impact do you have? Can you just go over the puts and takes there and how we should think about that impacting your results in the coming year?
Bob, you wanna address that, please?
Sure. Well, you saw there was more of an impact on the currency in the fourth quarter, mainly due to the d rop in the euro versus the US dollar, and we expect that to continue. On the other hand, all the forecasts I've been reading, coming up in fiscal 2023 could go the other direction with the dollar going down. You're gonna see ups and downs, you know. I would expect in the first quarter we'll see probably a similar impact to what we had in the fourth quarter, but after that, I would expect improvement.
Euros are the largest currency you are exposed to.
Yeah. Correct. Yeah. That's correct.
Okay. Then you also mentioned, I mean, you're retrofitting your facilities here in the US, and you're expecting higher CapEx this year. Can you quantify that?
Yes, we're probably gonna spend $2 million or something like that. What we're doing with the COVID situation, more and more of our employees are working from home. We have a lot of space, especially on the first floor that we're converting into manufacturing and moving all the private offices upstairs. The building was built in 1986. This is the first time we've done a major renovation, and it'll take 2 or 3 years, but probably capital expenditure will be $3-$5 million over that period.
Okay. Thank you. That was all for me. Thank you so much.
Thanks, Anja.
Our next question comes from Gokul Kannan with Infosys. Your line is open.
Hello.
Gokul Kannan, your line is now open. Please check your mute button. Our next question comes from Denis Amato, shareholder. Your line is now open.
Oh, thank you. Add my congratulations. Hi. Thanks for taking the call. I want to add my congratulations. That's a super quarter.
Thank you.
I just had two questions, one sort of a general one. Given the great quarter and given the really good backlog numbers, does anybody have any idea why the market reaction was so negative today?
Yeah, we don't, that's for sure. You know, the company's never done better than it's doing now. I think, in our 75-year history, by the way, this is our 75th year. I've been around 60 years. This is the most profitable year and quarter that we've ever had. With a $206 million backlog, you know, it looks like we'll do $250 or $255 million next year without any problem. I think we're on track to be a $500 million company here in the next 5 years and extremely profitable.
Yeah. I just wondered if you heard anything from analysts or shareholders which would indicate why anyone would have been disappointed with the results.
I think what's happening is that we have some major shareholders that have been on board for 10 years, and, you know, they're finally able to take a profit on their holdings, and you can't blame them for that. I think that's what's happening. There's some of them bailing. The good news is that for every share that's sold, there's also a buyer.
My second question is for Robert Ben. It appears that in this quarter, you've segregated out for the first time cash and investments rather than all cash and equivalents. Can you comment on two things? What does the investment component consist of? And two, given the fact that we now have finally positive interest rates on short-term treasuries, et cetera, what do you see going forward as your ability to finally earn a decent return on all the cash that you've been holding?
Yeah, you just noted that we did move some of our money into investments. Specifically, it's a CD. As rates go up, you know, we'll continue to look at that. You know, I would expect that, given some of the increases that we should expect this year, by the end of the fiscal year, we should get some more investment income than certainly that we've had in the recent past.
It seems like, you know, 90-day T-bills now are at, like, 2.5%, actually better than CD rates, and more liquidity. Is there ability to put more of that, the other money in, into, you know, short-term treasuries?
Yes. There is that ability, and we're always looking at that. We have an investment committee that reviews that every quarter, so we'll certainly be looking at that. But, you know, as I mentioned in my remarks, we have over $25 million in cash in the U.S. and approximately $15 million overseas. So
Great.
We're constantly reviewing opportunities, and we'll do so going forward.
Okay. Those are my questions. Thanks.
Thanks very much.
Thank you.
Our next question comes from David Schneider, Private Investor. Your line is now open.
Hi. Thanks for taking my call. In looking at the May quarter and the fiscal year in general, just looking at cash flow from operations for the fiscal year total, it was, let's say, a very small percentage of net income. Just wondering what factors might change that going forward so that the company sees more cash flow from operations relative to net income.
Bob, you want to address that, please?
Sure. Well, obviously with cash flow from operations, there's quite a few things in there. The main drivers, of course, are net income, depreciation, accounts receivable, inventory, and accounts payable. As we saw in FY 2022, we had significant increases in accounts receivable and inventory specifically. Those were, as I mentioned in my remarks, the accounts receivable increase was largely just due to the growth in sales. We did keep our DSO fairly constant at approximately 39 days, so that was really a function of the sales increase. On the inventories, we talked about that. Greg mentioned, you know, in his area specifically that we're buying everything we can get in terms of components, so that we can stock up and ship our new products as quickly as possible.
In addition, our manufacturing business, as I mentioned, is doing similar things and has a lot of work in process, particularly in the semiconductor wafer fab area. I expect that to continue, but maybe at a lesser growth rate in FY 2023, and I certainly expect higher net income will help that. I think it's a combination of higher net income and managing our working capital as best as we can. As we've noted, you know, for reasons with the supply chain and a very high growth rate in the business, it's a bit challenging to keep that under. We're certainly doing our best.
Yeah. At least how I calculate it, your days inventory outstanding really for the last five quarters. It's been pretty flat for the last five quarters. You know, it does bounce around a little bit, but I think you're right on about pretty much the same thing with days sales outstanding and days payable outstanding. Cash conversion cycle, the way I calculate it was 153 days in the May quarter. It's been pretty steady for the last five quarters.
Yep.
Yeah, I guess as you describe it. Sorry.
No, I was just gonna say, I do expect improvement, though, in FY 2023 in cash flow from operations. I don't think I specifically said that, but definitely, I expect improvement.
Okay. Well, that's good news. Regarding the, you know, the word Ukraine did come up in the call once or twice, and given the unfortunate situation there, if we were to take a worst case scenario and just give it a zero going forward, how relevant would that be to the company?
It's very small. You know, it's a few hundred thousand dollars.
Okay. I just wanted to kinda get that out there. All right, that's all for me.
Thank you.
Our next question comes from P. Ross Taylor III, ARS Investment Partners. Your line is now open.
Thank you. Gentlemen, how are you guys doing?
Oh, we're doing well. Thank you.
I was gonna say, you beat my estimates and my expectations for the quarter. If I had to guess, I would say I think you're seeing selling. It looked almost like a retail type thing where people were looking for something, they didn't get it, and they're running out the door because they don't necessarily understand what they own. Away from that real quick, you mentioned some things I thought were very interesting and no one has followed up. You talked about a white label opportunity in the wind turbine space. Is that a domestic or a foreign customer you'd be white labeling for?
Greg, you wanna answer that?
Sure. It's the private label thing we're talking about with a major wind turbine manufacturer. It'd be a global agreement. The products are used in all their wind turbines. We already have beta sites confirmed. As I mentioned before, we're still in the design stage, but actually to start out, it'll be North America, India and Spain will be the three sites that we'll be testing the product for them.
Okay. I'm sure you can't tell us who the customer is, but is the customer a domestic U.S. player or a European player?
It's a global player, but mainly Europe.
Okay. Oh, great. That's actually really exciting. That's not what I thought.
That's very exciting.
I didn't think you'd answer that question that way. Okay. Looking at some other things, obviously you just, you guys just commented on the fact that you've been building up inventories. This is a very common thing I've seen in a lot of my companies, given the uncertainty and people who are looking at rapid ramp-ups. What do we need to see in your supply chain to get it so that you'll be comfortable pulling those inventories down to more historic levels and thus converting them into cash this next year?
Well, I think that, you know, we have a lot of issues on, particularly on integrated circuits that we use in the ultracapacitor module. Delivery is like 48 weeks, and we're just sort of hand to mouth. Anytime we have chance to put inventory in, we do. For instance, with the ultracapacitors, we bought all the ultracapacitors, well in advance that we know that we have orders coming through for. We'll continue that as long as there are shortages out there. We'd much rather have inventory so that we can address our customers' demand. And as you know, we have $40 million in cash, so that's not an issue.
Mm-hmm. No, it's what you're doing is prudent. It's just, it seems that at some point, eventually we'll get to a more normalized supply chain, and as that happens, we should expect to see, I would think, cash conversion out of there that could be meaningful overall.
No, I think that's correct. I think you'll see this year we'll be sort of cash flow neutral, maybe spend $a few million, and then in years to come, we're gonna be, you know, cash flow positive and building a substantial amount of cash.
Cool. Now, you talked about a soft launch in the second Canon series tube. What do you think? You know, these tubes have always been a little bit of a holy grail out there. You've got a great product. You haven't been able to really drag the top line across that you would hope to have dragged. Canon, are you seeing any market reaction to what you're in, and what kind of top-line leverage do you think we should be seeing as you bring the second tube on and perhaps additional tubes on over this fiscal year?
Like I said, we do expect the growth to be gradual. We do, however, anticipate you know, a pretty nice level of growth in our fiscal year in that business segment, and that'll be partially from the G, the new tube. Part of that will come from the additional D sales. You know, now that we have the G and the D, we can cover more of the Canon market. People who might have been reluctant to take their systems off of the service contracts with Canon can now do that and know that they can get both, or the almost the majority of their systems covered by a third-party service company.
Mm.
With that, we would anticipate some growth in those sales. For us, again, really the bigger driver of growth is going to be that Siemens program.
Okay. You did comment, yes, obviously, and what kind of time horizon are we looking at for Siemens, do you think?
Yeah. We're hoping to have the first one out, which is the Straton Z. We're hoping to have that out before the end of this calendar year. We've got a few that are ready right now that are gonna go first to a close friend to test in their location. If they perform as we anticipate they will, we will look at beta sites for them. If that all goes well, we'll see those launch in the next, you know, three to six months. The bigger part of the line is the MX series. There's three tubes in that, and that'll be in calendar year 2023. We're still a little bit of ways on that.
Okay. When they launch, you commented you think you get mid- to high-20s% operating margin on the recovery after what happened in the last quarter. Do you think that as you launch them, that operating margin should be able to stay the same? Do you think you grow it? You know, the division's operating below-
Right
some of the other areas in the company.
Definitely. Yeah, we're really counting on that Siemens program to help improve. When you say operating margin, I'm talking about gross margin?
Yes. Yeah.
Yeah.
That's right.
We do anticipate that going up for the two reasons. One is that, when we sell them, it has nice margin. Two, it takes up some of the excess capacity that we have in our plant.
Mm.
We've told you before that we've got the capacity to make up to 1,000 tubes over three shifts, and we're still making less than 300. The more tubes we can get into production, the lower the cost per tube goes. It's a win on the top line, and it's a win at the gross margin line.
Sounds fantastic. Two other areas. Can we talk about the market potential and the ramp-up from T-Mobile and others in the wireless space?
Greg, you wanna address that?
Sure. I think it's gonna be similar. It'll obviously start with North America. We do have Verizon and AT&T in line to do some beta site testing this fall. The ramp-up, like I kinda mentioned, I think production orders we'll start seeing in our Q3 from T-Mobile. Then we'll be finishing up the beta site testing with Verizon and AT&T, you know, at the end of our fiscal year. I will add, in addition to that, we are in the process of a pretty large program with a critical facility, a hospital network here in Illinois that will also use this product for the same generator, same type of situation. That would be also something we'd probably see not till Q3 or Q4.
Okay
We continue to add customers, continue to do the beta site testing. Again, as I mentioned before, similar to the ULTRA3000 where we had just absolutely excellent results in terms of the beta site testing and lack of failures, we're seeing that with this too. I think it's gonna go from zero to a hundred like ULTRA3000 did, but I don't think that's gonna be till probably third or fourth quarter of this fiscal year.
Okay. Obviously it's a pretty exciting area. Will you talk about or are you comfortable talking about per site revenue that you expect out of this?
I'm not gonna talk about numbers, but for example, the ULTRA3000, there's 18 per turbine. With this, in terms of the cell tower, there's only one per cell tower. But obviously-
Okay
There's enough cell towers. Yeah. That's kind of the mix, so.
Okay. Let's switch over to the rail engine, the electric rail engine.
Mm-hmm
Basically what you're looking at is about 1 million tubes for rail or 2-4 per engine? Is that what we're looking at right now?
Yeah. That's approximately our content. Now, as they build these out, these are what I'll call commuter trains.
Mm-hmm
Those are used in either shipyards or the one from LaFox to Chicago. What they're developing now, what we're doing on these calls is obviously for long-range trains, you know, hauling products across the United States. Our contact with that will obviously be a lot more because you're gonna need a lot more lithium modules, so. Right now
How mu-
$1.1-$1.2 million is approximately our content today.
$1.2 million is kind of like what you think of as you said is a commuter rail or a switching type engine?
Yeah.
How much? I mean, obviously the engines you're talking about, I assume you're using the ones that one sees when you're out west and the trains go for two miles or something. That's the type of use you're talking about?
2 miles or farther. Yeah.
Yeah.
We call them long-range. Again, when I mentioned earlier in the call the access, if you will, that we have to these types of programs. I mean, we're talking about this program, and then the second half of the call is for new products, and that would be for what's called long-range electric locomotives. Right now, the content there will be much higher than 1.2. It's amazing the number of cells they're talking about right now to run that locomotive that far.
Would it be wrong to think it could be an order of magnitude?
Yes, I don't know what that, you know, order of magnitude would be. I don't know if it's five times, six.
Okay.
more comfortable with what that'll be, I'll share that obviously, as we get closer to a product.
Okay. Well, that's a hugely exciting opportunity that, you know, switching in the back of it, that's obviously a huge market from the number of engines that are operating. Okay, and then-
And -
Go ahead.
Well, I was just gonna say, you know, they all have initiatives, whether internally or government, you know, to get their emissions down, to certain levels by 2030 and 2050. It's really one of those markets where it's not a matter of if, a matter of when. It's just
Mm-hmm.
You hit it on the head. It's really exciting to be here in LaFox, downtown LaFox, and be working with these type of programs. Then read press releases where these huge railroads are announcing how many electric locomotives you're gonna buy, and you know that you're gonna get potentially over half of that, because today the two main providers of those is, you know, GE Transportation and Progress Rail. We're in an amazing partnership with Progress Rail.
Okay. That's, as I say, you guys are really knocking the cover off the ball in here. As I said, I would agree. I don't quite understand why the market is running away, like they've just seen a mouse. I think that gives opportunity for those not in to get in because I'm not. Just listening to you guys, you're talking about getting to $500 million, you should be able to retain or grow your operating margins as you push that direction, I would think.
Absolutely.
Okay. Well, that becomes huge. Okay, you know, especially on a small share count. Okay, I'll pass it on to anyone else who wants to pick up.
Thanks very much.
Thank you. Take care.
Thank you. As a reminder, to ask a question at this time, please press star then one on your touchtone telephone. Our next question comes from Walter Schenker with MAZ Partners. Your line is now open.
Hi, Walter.
Thank you. Hi. Let me get you up to speed. Ed, you've indicated, again, I think you said it, that the current fiscal year revenues could be, and it's my number, but you've said it, roughly the $250 million range. It's the year's-
That's correct.
The outlook is good.
Yes.
This was a $60 million+ quarter, and so to get to $250, you need on average four $60+ million quarters.
Yes.
This quarter had some issues, positive and negative. Increased freight, a tough quarter for medical. The question is, if I look at how profitable you were this quarter with $60+ million in revenues, is it reasonable to say this is how you would expect, and this is the level of profitability broadly, a lot of moving pieces, you would expect in $60-$65 million quarters?
Yeah.
I'm backing you into making a forecast which you don't wanna make. I can ask questions which you might be able to answer.
No, I think, you know, I think the level of profitability will be sustained just about where it is now. With a $206 million backlog going into the year, you know, we're pretty certain we can make that 250-255 number without too much trouble.
Okay. Not that it wasn't great, but there were some moving pieces. Is there an ability to get either a surcharge or somewhat raise prices to offset you and everybody else is having freight cost issues, was a couple of % on margins. Is there things you can do to recover some of that or not?
Yes. You know, Jens, you want to address that because most of the freight issues are in Canvys.
Sure. Thanks. Yeah. We have of course a contract with our customers, and as soon as they expire, you know, we increase pricing, of course. You know, we will pass on the freight cost increases from our partners and from the freight forwarders. We are very transparent there. You know, if our customers, for example, say that they can do it cheaper, you know, we are not making money on freight. We are happy that they take care of the import. Other than that, you know, we have actually I think pretty good freight rates in general because we have containers going, you know, from Asia to Europe and to North America all the time, right?
We collect it from different suppliers, and therefore, you know, we should have, you know, very fair freight rates even so they are up like everyone's freight rates are. Yes, we will see opportunities where we can pass it on to our customers. Absolutely.
Hey, clearly, Jens, the dog does not like the freight.
No.
The dog came for me.
No, the dog is because someone's working on my deck and she hates it. Sorry about that. Last comment, and it's not a question. I know Ed and Wendy, every time we meet, I suggest that the board consider at some point a buyback. If the stock stays around these levels, which is a little over 11 times maybe annualizing the fourth quarter, again, I know in the past you've wanted to wait till you got to cash flow neutral to positive. During the course of this year, you should get there. I would again, as a shareholder, suggest one use of cash is buying back at least some stock going forward. It's, I keep saying it, and you keep smiling at me. Anyhow.
It's a topic of discussion at every board meeting. That's all I can tell you.
Okay. Thanks a lot, Ed and Wendy.
Thanks, Walter.
Thanks, Walter.
Our next question comes from Gokul Kannan with [Emphasis]. Your line is now open.
Hello.
Gokul, please check your mute button. Our next question comes from Maricar Goco with FactSet. Your line is now open. Maricar, please check your mute button. I'm currently showing no further questions at this time. I'd like to turn the call back over to Ed Richardson for closing remarks.
Thanks, Shannon. We appreciate your patience and support. You know, it's been a long road, but we're really excited about the future. Reaching this level of performance has taken longer than we anticipated for sure, but we're very excited about what's going on and the tremendous backlog we have. We understand the story is complex, so anytime give us a call and we're happy to answer your questions. Or better yet, come and see us. It's easier to show you what we do than to tell you about it. We look forward to our fiscal 2023 first quarter performance with you in October. Thanks very much.
This concludes today's conference call. Thank you for participating. You may now disconnect.